1. Gilead Sciences and GlaxoSmithKline are developing new HIV drugs that are expected to compete against one another. Gilead’s dolutegravir/bictegravir combination could secure FDA approval by February 12, while GlaxoSmithKline’s combination of 3TC and dolutegravir is expected to reach pharmacy shelves by the second half of 2019. (Reuters)
2. GlaxoSmithKline’s head of R&D, Patrick Vallance, will leave the company to become the new chief scientific adviser to the British government. (Reuters)
3. Bausch + Lomb, a subsidiary of Valeant Pharmaceuticals International, received approval for Vyzulta, a drug to treat intraocular pressure in patients with glaucoma or ocular hypertension.
4. Johnson & Johnson launched its Health Partner platform, which is designed to help patients prepare for knee, hip, and weight-loss surgeries as well as facilitate recovery. (MassDevice)
5. ICYMI: Publicis Health global chief creative officer, Graham Mills has decided to retire from the agency network. (Clios)
